TipRanks
Advertisement
Advertisement

SLGL Stock Latest News

Sol-Gel Technologies Sets October 14 KOL Investor Day for SGT-610
Company AnnouncementsSol-Gel Technologies Sets October 14 KOL Investor Day for SGT-610
3h ago
6K
SLGL
Sol-Gel’s Patidegib Gel Nears Key Milestone With Completed Phase 3 Gorlin Syndrome Study
PremiumCompany Announcements
Sol-Gel’s Patidegib Gel Nears Key Milestone With Completed Phase 3 Gorlin Syndrome Study
12d ago
SLGL
Sol-Gel Technologies Reaches Last-Patient Milestone in Phase 3 Gorlin Syndrome Trial
PremiumCompany Announcements
Sol-Gel Technologies Reaches Last-Patient Milestone in Phase 3 Gorlin Syndrome Trial
13d ago
6K
SLGL
Sol-Gel Technologies announces last patient visit in SGT-610 trial
PremiumThe Fly
Sol-Gel Technologies announces last patient visit in SGT-610 trial
13d ago
SLGL
Sol-Gel Therapeutics: Steady SGT-610 Execution and Capital-Efficient Growth Strategy Drive Price Target Increase to $195 and Support Buy Rating
PremiumRatings
Sol-Gel Therapeutics: Steady SGT-610 Execution and Capital-Efficient Growth Strategy Drive Price Target Increase to $195 and Support Buy Rating
1M ago
SLGL
Sol-Gel Technologies Posts Q2 Loss as Pivotal Gorlin Syndrome Trial Advances Toward Late-2026 Readout
PremiumCompany AnnouncementsSol-Gel Technologies Posts Q2 Loss as Pivotal Gorlin Syndrome Trial Advances Toward Late-2026 Readout
1M ago
6K
SLGL
Maintains Buy Rating and $184 Price Target on SGT-610’s Promising Gorlin Syndrome Opportunity
Premium
Ratings
Maintains Buy Rating and $184 Price Target on SGT-610’s Promising Gorlin Syndrome Opportunity
1M ago
SLGL
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
Premium
TipRanks Newswire
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
2M ago
PTN
CRNX
Sol-Gel Technologies initiated with an Outperform at Mizuho
PremiumThe Fly
Sol-Gel Technologies initiated with an Outperform at Mizuho
3M ago
SLGL
Sol-Gel Technologies initiated with a Buy at TD Cowen
PremiumThe Fly
Sol-Gel Technologies initiated with a Buy at TD Cowen
4M ago
SLGL
Analyst Maintains Buy on Sol-Gel, Citing SGT-610 Progress and Solid Cash Runway with Unchanged $184 Price Target
PremiumRatings
Analyst Maintains Buy on Sol-Gel, Citing SGT-610 Progress and Solid Cash Runway with Unchanged $184 Price Target
4M ago
SLGL
Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year
PremiumThe Fly
Sol-Gel Technologies reports Q1 EPS ($1.31) vs. ($3.20) last year
4M ago
SLGL
Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering
PremiumCompany AnnouncementsSol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering
4M ago
6K
SLGL
Sol-Gel Technologies Prices $33.1 Million Oversubscribed Equity Offering to Advance SGT-610
Premium
Company Announcements
Sol-Gel Technologies Prices $33.1 Million Oversubscribed Equity Offering to Advance SGT-610
6M ago
6K
SLGL
Sol-Gel Technologies 459K share Spot Secondary priced at $72.00
Premium
The Fly
Sol-Gel Technologies 459K share Spot Secondary priced at $72.00
6M ago
SLGL
Sol Gel Technologies trading resumes
PremiumThe Fly
Sol Gel Technologies trading resumes
7M ago
SLGL
Sol Gel Technologies trading halted, volatility trading pause
PremiumThe Fly
Sol Gel Technologies trading halted, volatility trading pause
7M ago
SLGL
Sol-Gel Technologies: Upside-Driven Buy on SGT-610’s Orphan Gorlin Syndrome Opportunity and Repriced Peak Sales Potential
PremiumRatings
Sol-Gel Technologies: Upside-Driven Buy on SGT-610’s Orphan Gorlin Syndrome Opportunity and Repriced Peak Sales Potential
8M ago
SLGL
Sol-Gel Technologies price target raised to $110 from $50 at H.C. Wainwright
PremiumThe Fly
Sol-Gel Technologies price target raised to $110 from $50 at H.C. Wainwright
8M ago
SLGL
Sol-Gel: SGT-610 as Core Value Driver Underpins $50 Target and Buy Rating Despite Pipeline Setbacks
PremiumRatingsSol-Gel: SGT-610 as Core Value Driver Underpins $50 Target and Buy Rating Despite Pipeline Setbacks
9M ago
SLGL
Sol-Gel Technologies Updates Clinical Pipeline Following Phase 1b Results
Premium
Company Announcements
Sol-Gel Technologies Updates Clinical Pipeline Following Phase 1b Results
10M ago
6K
SLGL
Sol-Gel decides not to advance SGT-210 development in Darier disease
Premium
The Fly
Sol-Gel decides not to advance SGT-210 development in Darier disease
10M ago
SLGL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >